Back

Risk prediction of atrial fibrillation in the community combining biomarkers and genetics

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 6 Genetic Causes ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Christin Susanna Boerschel

The University Medical Center Hamburg-Eppendorf, Hamburg (Germany)

9 More presentations in this session

Presentation thumbnail
Performance of the HAS-BLED, ATRIA, and PRECISE-DAPT Bleeding Risk Scores in Atrial Fibrillation Patients Using Antiplatelet Agents or Oral Anticoagulants
Mr J. Choi (Busan, KR)
Abstract Slides
Presentation thumbnail
Dabigatran versus vitamin K antagonists in patients with atrial fibrillation and valvular heart disease
Doctor J. Strange (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in the elderly asian patients with atrial fibrillation
Doctor T. Chao (Taipei, TW)
Abstract
Presentation thumbnail
Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: an ARISTOPHANES study analysis
Ms A. Kang (Princeton, US)
Abstract Slides
Presentation thumbnail
Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study
Professor H. Bonnemeier (Luebeck, DE)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 6

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Atrial-tissue (genetic, molecular, and histological) signs of atrial cardiomyopathy
thumbnail
Congress Presentation
Atrial cardiomyopathy: a valuable concept or a passing trend?
thumbnail
Congress Presentation
Whole exome sequencing in young atrial fibrillation patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources